For Patients


 

Short summary

In this clinical study, the efficacy of the drug hydrochlorothiazide will be tested in the recurrence prevention of calcium containing kidney stones.

 

Content and aim of this study:

Kidney stones are a global health problem, around 10% of humans are affected by a kidney stone episode in their life. Kidney stones are extremely painful, relapse frequently and cause high health care expenditures. Therefore, a cheap and effective approach to prevent kidney stones is highly desired.

Approximately 80-90% of all kidney stones contain calcium, an increased excretion of calcium in the urine is the most common metabolic disturbance. Thiazide diuretics, like hydrochlorothiazide, reduce the excretion of calcium in the urine and are used since decades in the prevention of calcium-containing kidney stones. The efficacy of thiazide diuretics in the prevention of kidney stones was tested in several clinical studies in the past. However, these studies did not meet current quality standards for clinical studies, included only small amounts of patients and the doses of the medications used was very high.

 

Scientific and economic importance of this study:

With the help of this clinical trial we will obtain critical information for the treatment of kidney stone disease, one of the most frequent human diseases. The results of this trial will affect kidney stone patients around the world.

 

Who can participate?

Any adult with at least 2 kidney stones (containing at least 50% of calcium) in the last 10 years.

The NOSTONE clinical trial takes place in the following hospitals:  Map of the involved centres (click here)

 

For more detailed information please visit clinicaltrials.gov or kofam.ch.